The humoral immune system has a key prognostic impact in node-negative breast cancer - PubMed (original) (raw)
Multicenter Study
. 2008 Jul 1;68(13):5405-13.
doi: 10.1158/0008-5472.CAN-07-5206.
Affiliations
- PMID: 18593943
- DOI: 10.1158/0008-5472.CAN-07-5206
Free article
Multicenter Study
The humoral immune system has a key prognostic impact in node-negative breast cancer
Marcus Schmidt et al. Cancer Res. 2008.
Free article
Abstract
Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with principal component analysis. Distinct patterns led to the hypothesis of a prognostic role of the immune system in tumors with high expression of proliferation-associated genes. In multivariate Cox regression analysis, the proliferation metagene showed a significant association with metastasis-free survival of the whole discovery cohort [hazard ratio (HR), 2.20; 95% confidence interval (95% CI), 1.40-3.46]. The B-cell metagene showed additional independent prognostic information in carcinomas with high proliferative activity (HR, 0.66; 95% CI, 0.46-0.97). A prognostic influence of the B-cell metagene was independently confirmed by multivariate analysis in a first validation cohort enriched for high-grade tumors (n = 286; HR, 0.78; 95% CI, 0.62-0.98) and a second validation cohort enriched for younger patients (n = 302; HR, 0.83; 95% CI, 0.7-0.97). Thus, we could show in three cohorts of untreated, node-negative breast cancer patients that the humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast.
Similar articles
- Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG. Schmidt M, et al. Breast Cancer Res Treat. 2011 Feb;125(3):637-46. doi: 10.1007/s10549-010-0856-5. Epub 2010 Mar 30. Breast Cancer Res Treat. 2011. PMID: 20352488 - A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity.
Oh E, Choi YL, Park T, Lee S, Nam SJ, Shin YK. Oh E, et al. Breast Cancer Res Treat. 2012 Apr;132(2):499-509. doi: 10.1007/s10549-011-1626-8. Epub 2011 Jun 11. Breast Cancer Res Treat. 2012. PMID: 21667120 - Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
Heimes AS, Madjar K, Edlund K, Battista MJ, Almstedt K, Elger T, Krajnak S, Rahnenführer J, Brenner W, Hasenburg A, Hengstler JG, Schmidt M. Heimes AS, et al. Breast Cancer Res Treat. 2017 Sep;165(2):293-300. doi: 10.1007/s10549-017-4327-0. Epub 2017 Jun 5. Breast Cancer Res Treat. 2017. PMID: 28585074 - Coordinates in the universe of node-negative breast cancer revisited.
Schmidt M, Hengstler JG, von Törne C, Koelbl H, Gehrmann MC. Schmidt M, et al. Cancer Res. 2009 Apr 1;69(7):2695-8. doi: 10.1158/0008-5472.CAN-08-4013. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318558 Review. - The impact of expression profiling on prognostic and predictive testing in breast cancer.
Reis-Filho JS, Westbury C, Pierga JY. Reis-Filho JS, et al. J Clin Pathol. 2006 Mar;59(3):225-31. doi: 10.1136/jcp.2005.028324. J Clin Pathol. 2006. PMID: 16505270 Free PMC article. Review.
Cited by
- Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells.
Liu Z, Petinrin OO, Chen N, Toseef M, Liu F, Zhu Z, Qi F, Wong KC. Liu Z, et al. BMC Infect Dis. 2024 Oct 3;24(1):1099. doi: 10.1186/s12879-024-10000-3. BMC Infect Dis. 2024. PMID: 39363208 Free PMC article. - Transcriptome-based identification of key actin-binding proteins associated with high metastatic potential in breast cancer.
Müller C, Oliveira-Ferrer L, Müller V, Schmalfeldt B, Windhorst S. Müller C, et al. Front Mol Biosci. 2024 Aug 30;11:1440276. doi: 10.3389/fmolb.2024.1440276. eCollection 2024. Front Mol Biosci. 2024. PMID: 39281318 Free PMC article. - Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers.
Alfaro A, Catelain C, El-Masri H, Rameau P, Lacroix-Triki M, Scoazec JY, Marty V, Mosele F, Pistilli B. Alfaro A, et al. NPJ Breast Cancer. 2024 Sep 14;10(1):81. doi: 10.1038/s41523-024-00691-x. NPJ Breast Cancer. 2024. PMID: 39277640 Free PMC article. - High-dimensional multivariate analysis of variance via geometric median and bootstrapping.
Cheng G, Lin R, Peng L. Cheng G, et al. Biometrics. 2024 Jul 1;80(3):ujae088. doi: 10.1093/biomtc/ujae088. Biometrics. 2024. PMID: 39248122 - CD20highCD138low tumor-infiltrating lymphocytes predominantly related to cytokine‒cytokine receptor interactions are associated with favorable outcomes in neuroblastoma patients.
Qin LJ, Xu H, Li LP, Li SH, Xu SY, Chen K, Yang T, Wang FH, Zuo L, Zeng L, Wang HY. Qin LJ, et al. Heliyon. 2024 May 8;10(9):e30901. doi: 10.1016/j.heliyon.2024.e30901. eCollection 2024 May 15. Heliyon. 2024. PMID: 38774103 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical